RegCell Raises $37.3M to Propel Breakthrough S/F-iTreg Therapies Inspired by Professor Sakaguchi’s Discovery

RegCell is excited to announce that we have successfully raised $37,300,000 in our latest funding round, a milestone that underscores both the confidence of our investors and the promise of our groundbreaking research. Our company, founded on the pioneering discovery of Professor Shimon Sakaguchi, is dedicated to developing stable, functional-induced Tregs that are antigen-specific (S/F-iTregs). Unlike earlier approaches and even emerging CAR-Treg strategies, our innovative S/F-iTregs have been designed to overcome previous limitations by leveraging the inherent strengths of our founder’s discovery, thus ensuring enhanced stability and specificity in immune modulation. With this vital funding, we aim to accelerate the development and commercialization of our therapy, moving swiftly from preclinical studies to clinical trials. The funds will be allocated to expanding our research and development capabilities, enhancing our manufacturing processes, and scaling our team with top-tier talent in immunology and biotech innovation. Our broader mission is to address complex autoimmune disorders and transplant rejection challenges by fine-tuning the immune response with precision and reliability. We believe that our S/F-iTregs not only offer competitive advantages in safety and efficacy but also pave the way for a new era of targeted immunotherapies. This achievement marks a significant step forward in our journey, reinforcing our commitment to transforming patient care by harnessing the power of advanced cellular therapies. As we embark on this exciting phase, we remain dedicated to scientific excellence, transparency, and patient-centric innovation, confident that the future of therapeutic Tregs is brighter than ever.